2024
The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment
Schoretsanitis G, Correll C, Agorastos A, Sanchez A, Erzin G, Grigoras R, Benussi M, Gondek T, Guloksuz S, Højlund M, Jerotic S, Kilic O, Metaj E, Sidhu D, Skandali N, Skuhareuski A, Tveito M, Wolthusen R, Communication and Publications E, Chumakov E, de Filippis R. The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment. The World Journal Of Biological Psychiatry 2024, 25: 342-351. PMID: 38905131, DOI: 10.1080/15622975.2024.2367138.Peer-Reviewed Original ResearchConceptsEuropean Psychiatric AssociationAntipsychotic treatmentPsychiatrists' attitudesTherapeutic drug monitoringEarly-career psychiatristsExploratory factor analysisBenefit of therapeutic drug monitoringPsychiatric AssociationAntipsychoticsNegative expectationsAssociated with frequencyTDM useDrug monitoringTherapeutic drug monitoring useFactor analysisBeliefs of patientsHigh-income countriesLow-/middle-income countriesResponse varianceClinical benefitClozapineOutpatient settingLinear regression analysisClinical settingPsychiatrists
2023
Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions
van der Horst M, Meijer Y, de Boer N, Guloksuz S, Hasan A, Siskind D, Wagner E, consortium C, Müderrisoğlu A, Privat A, Bouhuis A, Hasan A, Jongkind A, Gonzalez-Pinto A, Santacana A, D'Agostino A, Ertugrul A, Yağcioğlu A, Crespo-Facorro B, Sanchez-Barbero B, Spuch C, Morgenroth C, de Pinedo C, Casetta C, Bousman C, Pantelis C, Ovejas-Catalán C, Garcia-Rizo C, Okhuijsen-Pfeifer C, Cohen D, Ristic D, Beld E, Repo-Tiihonen E, Wagner E, Jeger-Land E, Vilella E, Bekema E, Sepúlveda S, Seghi F, Wiedenmann F, Martini F, Serio F, Vairano F, Mercuriali G, Boido G, Yoca G, van Beek H, Gijsman H, Tuppurainen H, Everall I, Novakovic I, Zorrilla I, Erdoğan I, Sapienza J, Bogers J, Tiihonen J, Vázquez-Bourgon J, van Os J, Schneider-Thoma J, Luykx J, Grootens K, Mar-Barrutia L, Martorell L, Bak M, Spangaro M, de Vos M, de Koning M, Garriga M, Lähteenvuo M, Bosia M, van der Horst M, Babaoğlu M, Veereschild M, Manchia M, Edlinger M, Fuentes-Pérez P, Paribello P, Lopez-Pena P, Kahn R, Cavallaro R, Veerman S, Gutwinski S, Schreiter S, Ripke S, Baltanás T, Oviedo-Salcedo T, Hallikainen T, Görlitz T, Alink W, Ayhan Y, Okhuijsen-Pfeifer C, Luykx J. Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions. Psychiatry Research 2023, 330: 115539. PMID: 37988817, DOI: 10.1016/j.psychres.2023.115539.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsClinical factorsDrug reactionsPrevalence ratesCommon adverse drug reactionsWeight gainSignificant weight gainMulti-center studyImproved treatment outcomesClozapine blood levelsClozapine monotherapyClozapine treatmentLower BMIBlood levelsTreatment outcomesHigh prevalencePrevalenceMean numberYounger participantsSex differencesParticipantsTreatmentComprehensive dissectionConstipationHypersalivationThe effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service
Ferrara M, Guloksuz S, Hazan H, Li F, Tek C, Sykes L, Riley S, Keshavan M, Srihari V. The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service. Schizophrenia Research 2023, 260: 198-204. PMID: 37688984, DOI: 10.1016/j.schres.2023.08.005.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis servicesLength of stayUntreated psychosisPsychiatric hospitalizationFirst-episode servicesDuration of hospitalizationIncidence rate ratiosNon-affective psychosisNew Haven areaPoisson regression modelsPatient characteristicsHospitalization ratesRecent onsetMedical recordsHospitalizationEffect of durationNegative binomial regressionSpecialized treatmentPsychosisRate ratioBinomial regressionAdmissionDUPEnrollmentFirst yearAddressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium
Koops S, Allott K, de Haan L, Chen E, Hui C, Killackey E, Long M, Moncrieff J, Sommer I, Stürup A, Wunderink L, Begemann M, van der A J, Bakker P, Beer F, Begemann M, van Beveren N, Boonstra T, Brand B, Djordjevic M, Franke S, Gangadin S, Guloksuz S, Haan L, van ‘t Hag G, Hamers I, van der Heijden-Hobus I, Hoornaar R, Huizer K, Kikkert M, Koops S, Lokkerbol J, Marcelis M, Oomen P, van Os J, Rosema B, Sommer I, Smit F, Veling W, Voppel A, Albert N, Karlsen M, Nordentoft M, Speyer H, Stürup A, Allott K, Killackey E, O’Donoghue B, Stainton A, Cooper R, Conneely M, Grünwald L, Haynes N, Horowitz M, Mason J, Long M, Moncrieff J, Priebe S, Stansfeld J, Vasiliki G, Chen E, Hui C, Wunderink L, Liu C, Berna F, Foucher J. Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium. Schizophrenia Bulletin 2023, 50: 5-8. PMID: 37625022, PMCID: PMC10754158, DOI: 10.1093/schbul/sbad112.Peer-Reviewed Original ResearchAn international research agenda for clozapine-resistant schizophrenia
Luykx J, Gonzalez-Diaz J, Guu T, van der Horst M, van Dellen E, Boks M, Guloksuz S, DeLisi L, Sommer I, Cummins R, Shiers D, Lee J, Every-Palmer S, Mhalla A, Chadly Z, Chan S, Cotes R, Takahashi S, Benros M, Wagner E, Correll C, Hasan A, Siskind D, Endres D, MacCabe J, Tiihonen J. An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry 2023, 10: 644-652. PMID: 37329895, DOI: 10.1016/s2215-0366(23)00109-8.Peer-Reviewed Original ResearchConceptsClozapine-resistant schizophreniaQuality of lifeTreatment optionsTreatment-resistant symptomsThird of patientsNew treatment optionsHealth care providersMiddle-income countriesFunctional outcomeInterventional studyUnmet needEpidemiological researchTranslational approachDiagnostic testsPatientsSchizophreniaHealth policyEarly detectionOptionsSymptomsDiagnosisTrialsAssociations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
Lin B, Pinzón-Espinosa J, Blouzard E, van der Horst M, Okhuijsen-Pfeifer C, van Eijk K, Guloksuz S, Peyrot W, Luykx J, Hasan A, Wagner E, Pantelis C, Everall I, Ayhan Y, Babaoğlu M, Bak M, Alink W, Beld E, Bouhuis A, Edlinger M, Erdoğan I, Gutwinski S, Hallikainen T, Jeger-land E, Lähteenvuo M, de Koning M, Morgenroth C, Müderrisoğlu A, Oviedo-Salcedo T, Schreiter S, Repo-Tiihonen E, Tuppurainen H, Veereschild M, Veerman S, de Vos M, Cohen D, Bogers J, Anıl Yağcıoğlu A, Tiihonen J, Ripke S, Bousman C, Van Beek H, Okhuijsen-Pfeifer C, van der Horst M, van Eijk K, Ertuğrul A, Yoca G, Görlitz T, Grootens K, Leucht S, Narang A, Schneider-Thoma J, Kahn R, Bekema E, Kleymann P, Luykx J, Alizadeh B, van Amelsvoort T, Cahn W, de Haan L, Schirmbeck F, Simons C, van Os J, Rutten B, van Winkel R. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia. JAMA Psychiatry 2023, 80: 181-185. PMID: 36542388, PMCID: PMC9857760, DOI: 10.1001/jamapsychiatry.2022.4234.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsClozapineFemaleHumansMultifactorial InheritancePsychotic DisordersRisk FactorsSchizophreniaConceptsSchizophrenia spectrum disordersRisk ratioPolygenic risk scoresUnrelated healthy controlsRisk scorePRS-SCZClozapine useHealthy controlsOdds ratioCourse of illnessHigher likelihoodPsychosis liabilityClozapine prescribingClozapine prescriptionPharmacotherapy choicesClozapine treatmentObservational cohortMedication useAntipsychotic useAntipsychotic treatmentMAIN OUTCOMEMultinomial logistic regressionPrognostic studiesAntipsychoticsEarly intervention
2021
Medication strategies in first episode psychosis patients: A survey among psychiatrists
Kikkert M, Veling W, de Haan L, Begemann M, de Koning M, Sommer I, de Haan L, Veling W, van Os J, Smit F, Begemann M, Schuite‐Koops S, Marcelis M, Kikkert M, van Beveren N, Boonstra N, Rosema B, Bakker P, Gülöksüz S, Lokkerbol J, Brand B, Gangadin S, Geraets C, Hag E, Oomen P, Voppel A, van Amelsvoort T, Bak M, Been A, van den Bosch M, van den Brink T, Faber G, Grootens K, de Jonge M, Knegtering H, Kurkamp J, Mahabir A, Pijnenborg G, Staring T, Vaes W, Veen N, Veerman S, Wiersma S, Sommer I. Medication strategies in first episode psychosis patients: A survey among psychiatrists. Early Intervention In Psychiatry 2021, 16: 139-146. PMID: 33754470, PMCID: PMC9292219, DOI: 10.1111/eip.13138.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsHumansPsychiatryPsychotic DisordersRemission InductionSurveys and QuestionnairesConceptsFirst psychotic episodeMedication discontinuationMedication strategiesPsychotic episodeFirst-episode psychosis patientsEpisode psychosis patientsSubstantial practice variationFirst-episode patientsMonths of remissionFirst-episode psychosisSpecific treatment strategiesSubsample of patientsPractice of cliniciansMaintenance therapyEarly discontinuationPsychosis patientsAntipsychotic drugsEpisode psychosisTreatment strategiesReduced dosePractice variationLong-term effectsSame doseDiscontinuationMost guidelinesAntipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
Bak M, Drukker M, Cortenraad S, Vandenberk E, Guloksuz S. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis. PLOS ONE 2021, 16: e0244944. PMID: 33596211, PMCID: PMC7888647, DOI: 10.1371/journal.pone.0244944.Peer-Reviewed Original ResearchConceptsAntipsychotic-naive patientsBody weight changesBody weight gainWeight gainPsychiatric diagnosisNaive patientsWeight changeAntipsychotic useBodyweight gainAntipsychotic-naive groupMore weight gainDiagnosis of schizophreniaAntipsychotic switchMost antipsychoticsShort followSwitch studyMetabolic disturbancesClinical trialsOutcome measuresAntipsychoticsPatientsBody weightNaive groupSwitch groupDiagnosisStudy protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial
de Boer N, Guloksuz S, van Baal C, Willebrands L, Deenik J, Vinkers C, Rossum I, Zinkstok J, Wilting I, Zantvoord J, Backx F, Swildens W, Schouw M, Bogers J, Hulshof F, de Knijff R, Duindam P, Veereschild M, Bak M, Frederix G, de Haan L, van Os J, Cahn W, Luykx J. Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial. BMC Psychiatry 2021, 21: 4. PMID: 33402159, PMCID: PMC7783702, DOI: 10.1186/s12888-020-02992-4.Peer-Reviewed Original ResearchConceptsNetherlands Trial RegisterLifestyle interventionQuality of lifeTreatment inceptionOutcome measuresWeight gainAntipsychotic-induced weight gainSafety of metforminUse of metforminCommon adverse effectsSecondary outcome measuresPrimary outcome measureWeeks of treatmentBody weight lossMulti-center trialType 2 diabetesMajor health problemYears of ageSchizophrenia spectrum disordersTrials RegisterMetabolic syndromeOptimal management strategyExercise programMetformin treatmentDietary consultation
2020
A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)
Hark S, Jamain S, Schijven D, Lin B, Bakker M, Boland-Auge A, Deleuze J, Troudet R, Malhotra A, Gülöksüz S, Vinkers C, Ebdrup B, Kahn R, Leboyer M, Luykx J. A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). Journal Of Psychopharmacology 2020, 34: 524-531. PMID: 32126890, PMCID: PMC7222287, DOI: 10.1177/0269881120907972.Peer-Reviewed Original Research
2019
Organization framework and preliminary findings from the Athens First‐Episode Psychosis Research Study
Xenaki L, Kollias C, Stefanatou P, Ralli I, Soldatos R, Dimitrakopoulos S, Hatzimanolis A, Triantafyllou T, Kosteletos I, Vlachos I, Selakovic M, Foteli S, Mantonakis L, Ermiliou V, Voulgaraki M, Psarra E, Gülöksüz S, van Os J, Stefanis N. Organization framework and preliminary findings from the Athens First‐Episode Psychosis Research Study. Early Intervention In Psychiatry 2019, 14: 343-355. PMID: 31402581, DOI: 10.1111/eip.12865.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsCohort StudiesFemaleGreeceHumansLongitudinal StudiesMaleMiddle AgedPsychotic DisordersYoung AdultConceptsRisk factorsMild functional improvementLongitudinal cohort studySymptom severity criteriaPoor cognitive performanceOutcome of psychosisPreliminary findingsPatients 16Cohort studyAntipsychotic treatmentClinical pictureFEP patientsClinical managementFunctional improvementFamily historyEmergency unitBaseline presentationSeverity criteriaPsychiatric hospitalPsychotic disordersClinical InterviewDrug usePotential associationGene-environment interaction studiesBiochemical parametersPhenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort)
Pandit R, Cianci D, Hark S, Rossum I, Ebdrup B, Broberg B, Garcia‐Portilla M, Bobes J, Vinkers C, Kahn R, Guloksuz S, Huitema A, Luykx J. Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort). Acta Psychiatrica Scandinavica 2019, 140: 283-290. PMID: 31323113, PMCID: PMC6771865, DOI: 10.1111/acps.13074.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis patientsPsychosis patientsWeight gainSchizophreniform disorderAntipsychotic-induced weight gainFirst-episode patientsManagement of schizophreniaLower baseline weightMultivariable regression modelsWeight-reducing strategiesOptimization of treatmentRegression modelsMajor depression disorderPhenotypic factorsAmisulpride treatmentBaseline weightEurope (Syst-Eur) trialMost antipsychoticsDepression disorderYoung subjectsBody weightPatientsBetter efficacyYounger ageAIWGEffects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia: A Double-Blind, Placebo-Controlled Pilot Trial.
Kucukgoncu S, Guloksuz S, Tek C. Effects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia: A Double-Blind, Placebo-Controlled Pilot Trial. Journal Of Clinical Psychopharmacology 2019, 39: 182-184. PMID: 30747752, DOI: 10.1097/jcp.0000000000001012.Peer-Reviewed Original Research
2013
Clinical potential of cariprazine in the treatment of acute mania.
Altınbaş K, Guloksuz S, Oral E. Clinical potential of cariprazine in the treatment of acute mania. Psychiatria Danubina 2013, 25: 207-13. PMID: 24048386.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAnimalsAntipsychotic AgentsBipolar DisorderClinical Trials as TopicHumansPiperazinesConceptsAcute manic episodeAdverse eventsManic episodesTreatment-emergent adverse eventsD3 receptor activityFlexible-dose studyCommon adverse eventsSerious adverse eventsCommon side effectsAdditional therapeutic benefitSecond-generation antipsychoticsCariprazine treatmentDopamine agonismPlacebo armAcute maniaExtrapyramidal symptomsQTc prolongationGeneration antipsychoticsHistamine H1Novel antipsychoticsProlactin increaseMetabolic disturbancesClinical trialsClinical dataDopamine D2Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight loss
2012
Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?
Jauhar S, Guloksuz S, Andlauer O, Lydall G, Marques J, Mendonca L, Dumitrescu I, Roventa C, De Vriendt N, Van Zanten J, Riese F, Nwachukwu I, Nawka A, Psaras R, Masson N, Krishnadas R, Volpe U, European Federation of Psychiatric Trainees' Research Group. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? BMC Psychiatry 2012, 12: 27. PMID: 22463055, PMCID: PMC3337226, DOI: 10.1186/1471-244x-12-27.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsCognitive behavioral therapyUse of SGAsSecond-generation antipsychotic medicationsKnowledge of trialQuestionnaire-based studyAntipsychotic medicationAntipsychotic treatmentTreatment choicePatientsBehavioral therapyForms of psychotherapyOwn treatmentAntipsychoticsTreatmentPsychosisTrialsPsychiatry traineesEfficacyTrainees